Q3 2025 marked a breakthrough with FDA approval for a partner's product using CHSTM, a 10-year supply deal, and a 23 MSEK capital raise. Despite lower sales and continued losses, the company expects improved financials from new agreements and US expansion.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.